Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 11, 2013

View Archived Issues

M01ZH09 provides little protection against typhoid challenge

First report of HIV proviral DNA level modulation in response to AGS-004 immunotherapy

FOB Synthesis identifies novel anti-Acinetobacter carbapenem antibiotic

BiondVax receives European FP7 grant to develop lead influenza vaccine

Human Brain Project launched with inaugural summit in Lausanne

Preclinical pharmacokinetics characterized for novel candidate for metabolic disorders

OncoTherapy Science presents phase II results for OTS-102 in biliary tract cancer

Lundbeck and Otsuka begin phase III program for add-on therapy in Alzheimer's disease

Joslin Diabetes Center and Johnson & Johnson partner to identify therapeutic targets in diabetes

Novel compounds inhibit drug-resistant mutants of the influenza A virus M2 proton channel

Biota Pharmaceuticals discloses new DNA gyrase inhibitors for bacterial infection treatment

Linx Pharmaceutical reports discovery of apoptosis inhibitors

New kinesin-like protein KIF11 inhibitors discovered by Pharma Valley and Taiho

Seragon Pharmaceuticals patents new ER-alpha ligands

Genosco and Oscotec disclose new FLT3 kinase inhibitors

Dynavax begins first human trial of AZD-1419

Pergamum reports final data from phase I/II LL-37 study in chronic leg ulcers

Alkermes' ALKS-5461 receives fast track designation for major depressive disorder

Heptares/MorphoSys GPCR collaboration reaches first milestone

Relypsa announces topline data from second part of patiromer phase III trial

Cystic Fibrosis Foundation awards grant for BET bromodomain inhibitor research

Medivir selects a candidate drug for neuropathic pain

Rexahn Pharmaceuticals in-licenses oligonucleotide targeted drug delivery platform

Recruitment in phase III trial of novel mono-pegylated interferon alpha 2b under way

Japanese encephalitis vaccine prequalified by WHO for use in children

Evotec and Harvard form new research collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...